TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06916793: A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia

Sponsor: Chong Kun Dang Pharmaceutical · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 288 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT06916793 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06916793 Rescue Dossier →